GlaxoSmithKline, (GSK) the
UK’s biggest drug maker, has been
fined more than £37.6m by the
Competition and Markets Authority
for arranging deals between 2001
and 2004 to reduce competition
from generic drug manufacturers
with its antidepressant paroxetine,
according to a report in the BMJ.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 16 Feb 16
To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Feb 16
